MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival

Molecular Cancer Research

Volumn 12, Issue 9, 2014, Pages 1216-1224

  Grieb, Brian C ^a   Chen, Xi ^a   Eischen, Christine M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; MESSENGER RNA; PROTEIN MTBP; UNCLASSIFIED DRUG; CARRIER PROTEIN; MTBP PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; BIOSYNTHESIS; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84907271995     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0069     Document Type: Article

References (38)

1. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
2. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84.
3. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24:5652-7.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
5. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
7. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-26.
8. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009;27:4536-41.
9. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012;30:2615-23.
10. BoydMT, Vlatkovic N, Haines DS. Anovel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J Biol Chem 2000;275:31883-90.
11. Iwakuma T, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM, et al. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene 2008;27:1813-20.
12. Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga J, et al. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene 2010;29:3287-96.
13. Grieb BC, Gramling MW, Arrate MP, Chen X, Beauparlant SL, Haines DS, et al. MTBP is a novel oncogenic protein that interacts withMYCto promote tumorigenesis. Cancer Res 2014;74:3591-602.
14. Boos D, Yekezare M, Diffley JF. Identification of a heteromeric complex that promotes DNA replication origin firing in human cells. Science 2013;340:981-4.
15. Agarwal N, Tochigi Y, Adhikari AS, Cui S, Cui Y, Iwakuma T. MTBP plays a crucial role in mitotic progression and chromosome segregation. Cell Death Differ 2011;18:1208-19.
16. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53- dependent apoptosis and immortalization. Genes Dev 1998;12: 2424-33.
17. Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A 2011;108:3665-70.
18. Bouska A, Lushnikova T, Plaza S, Eischen CM. Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 2008;28:4862-74.
19. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9:313-25.
20. Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, et al. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res 2007;67:10736-43.
21. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
22. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2: 401-4.
23. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
24. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez- Angulo AM, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012;209: 679-96.
25. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
26. Agarwal N, Adhikari AS, Iyer SV, Hekmatdoost K, Welch DR, Iwakuma T. MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4. Oncogene 2013;32:462-70.
27. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, et al. MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat Cell Biol 2012;14:567-74.
28. Vlatkovic N, El-Fert A, Devling T, Ray-Sinha A, Gore DM, Rubbi CP, et al. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck. Cancer 2011;117:2939-50.
29. Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, et al. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol 2011;135:230-7.
30. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-25.
31. Isola J, Kallioniemi OP, Korte JM, Wahlstrom T, Aine R, Helle M, et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990;162:295-301.
32. King KL, Hwang JJ, Chau GY, Tsay SH, Chi CW, Lee TG, et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1998;13:273-9.
33. Hofmockel G, Tsatalpas P, Muller H, Dammrich J, Poot M, Maurer- Schultze B, et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 1995;76: 296-306.
34. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-13.
35. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2-11.
36. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8:976-90.
37. Dang CV. MYC on the path to cancer. Cell 2012;149:22-35.
38. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455:679-83.